Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 27:15:2243-2251.
doi: 10.2147/IDR.S357396. eCollection 2022.

Genetic Diversity and in vitro Activity of Aztreonam/Avibactam and Ceftazidime/Avibactam Against Carbapenem-Resistant Enterobacterales: A Multi-Center Study in Southwest China

Shan Sun  1 , Kai Chen  2 , Xuehua Kong  2 , Wenjun Tian #  3 , Siqiang Niu #  1
Affiliations

Genetic Diversity and in vitro Activity of Aztreonam/Avibactam and Ceftazidime/Avibactam Against Carbapenem-Resistant Enterobacterales: A Multi-Center Study in Southwest China

Shan Sun et al. Infect Drug Resist. .

Abstract

Purpose: This study aimed to understand the distribution characteristics of carbapenemase genes and assess the antimicrobial activities of aztreonam/avibactam (ATM/AVI) and ceftazidime/avibactam (CAZ/AVI) against carbapenem-resistant Enterobacterales (CRE) isolates in Chongqing, Southwest China.

Methods: CRE isolates and their clinical information were collected from 22 hospitals covering all the five regions across Chongqing between January 1, 2016 and December 31, 2017. PCR was used to screen for common carbapenemase genes. And minimum inhibitory concentrations (MICs) were determined by broth microdilution method.

Results: A total of 312 unduplicated CRE isolates (eg, 206 Klebsiella pneumoniae, 43 Escherichia coli, and 42 Enterobacter cloacae) were collected during the two-year study period. Among these CRE isolates, 92.3% carried carbapenemase genes, with a majority of isolates carrying single bla KPC-2 (47.1%) or single bla NDM/IPM (36.2%) and 8.9% of isolates carrying two or three carbapenemase genes. Notably, 95.6% (197/206) K. pneumoniae, 86.0% (37/43) E. coli and 88.1% (37/42) E. cloacae harbored carbapenemase genes. In addition, bla KPC-2 was prevalent in K. pneumoniae (70.4%), while bla NDM was predominant in E. coli (83.7%) and E. cloacae (78.6%). Besides, only metallo-β-lactamase (MBL) genes were detected in the CRE isolates from children. Overall, 0.0%, 48.1%, 59.0%, 61.5% and 63.1% of the CRE isolates were resistant to ATM/AVI, CAZ/AVI, nitrofurantoin, amikacin and trimethoprim/sulfamethoxazole, respectively. 99.7% of the total 312 isolates could be killed by ATM/AVI with the MIC 1 μg/mL, whereas CAZ/AVI showed good antibacterial activity (98.0% susceptible) against the bla KPC-2-carriers with the MIC50/90 values of 1/4 μg/mL.

Conclusion: The distribution features of carbapenemase genes in Chongqing were comprehensively illustrated in terms of species and sources of CRE for the first time in this multi-center study that covered all the geographical locations across Chongqing. ATM/AVI showed superior activity against all CRE isolates regardless of their genotype, whereas CAZ/AVI was active against almost all KPC-producers.

Keywords: aztreonam/avibactam; carbapenem-resistant Enterobacterales; carbapenemase genes; ceftazidime/avibactam.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
The MICs distribution of CAZ/AVI against 147 CRE isolates carrying single blaKPC gene.
Figure 2
Figure 2
The MICs distribution of ATM/AVI against 312 CRE isolates.
See this image and copyright information in PMC

References

    1. World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. Available from: https://www.who.int/medicines/publications/global-priority-list-antibiot.... Accessed September 7, 2020.
    1. CDC. Antibiotic resistance threats in the United States; 2019. Available from: https://www.cdc.gov/drugresistance/biggest-threats.html. Accessed September 7, 2020.
    1. Suay-García B, Pérez-Gracia MT. Present and future of carbapenem-resistant Enterobacterales (CRE) infections. Antibiotics. 2019;8(3):122. doi:10.3390/antibiotics8030122 - DOI - PMC - PubMed
    1. Nordmann P, Poirel L. Epidemiology and diagnostics of carbapenem resistance in Gram-negative bacteria. Clin Infect Dis. 2019;69(Suppl 7):S521–S528. doi:10.1093/cid/ciz824 - DOI - PMC - PubMed
    1. Zhang R, Liu L, Zhou H, et al. Nationwide surveillance of clinical carbapenem-resistant Enterobacterales (CRE) strains in China. EBioMedicine. 2017;19:98–106. doi:10.1016/j.ebiom.2017.04.032 - DOI - PMC - PubMed